Evaxion A/S (EVAX)
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 gl...
- Open
- 3.170
- High
- 3.200
- Low
- 3.100
- Prev. Close
- 3.100
- Volume
- 29.83K
- Turnover
- 93.67K
- Avg Price
- 3.140
- Bid/Ask Ratio
- 5.26%
- Amplitude
- 3.23%
- 52wk High
- 12.150
- Volume Ratio
- 3.05
- Turnover Ratio
- 0.53%
Evaxion A/S Analyst Rating
View moreForecast & Rating
Aug 27, 2026Price forecast
$11.25259.42%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Sep 4 at 11:28 AM
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering
- Global Report · Sep 1 at 11:32 AM
From Regional Bank Mergers to Psychedelic Meds: Inside the Market's Unclassified Corners
- Global Report · Sep 1 at 09:18 AM
Beyond the Aggregators: Value Chains in the Physical and Regulated Economy
- Global Report · Aug 30 at 11:34 AM
The Ultimate Leverage Game in AI Hardware: Moving Beyond Nvidia
- Global Report · Aug 30 at 09:16 AM
Biotech Bingo: Evaxion's AI Gamble and a Laser ETF Masquerading as Pharma
- PUBT · Aug 21 at 10:58 AM
Evaxion releases transcript of Q2 2026 business update and financial results call
